Oncocyte’s (IMDX) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Oncocyte (NASDAQ:IMDX) in a research report sent to investors on Tuesday,Benzinga reports. The firm currently has a $9.00 price target on the stock.

Several other equities analysts have also recently issued reports on the company. Wall Street Zen cut Oncocyte from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oncocyte in a research note on Wednesday, June 24th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Oncocyte currently has an average rating of “Hold” and an average price target of $10.50.

Oncocyte Price Performance

Shares of NASDAQ:IMDX opened at $4.30 on Tuesday. Oncocyte has a 1 year low of $2.33 and a 1 year high of $8.51. The company has a market cap of $140.70 million, a PE ratio of -2.89 and a beta of 1.79. The stock’s 50-day moving average is $4.97 and its 200 day moving average is $5.00.

Oncocyte (NASDAQ:IMDX) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.23) EPS for the quarter. The business had revenue of $0.24 million during the quarter.

Oncocyte Company Profile

Oncocyte (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.

Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows.